Atossa Therapeutics (ATOS) to Release Earnings on Tuesday

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) is projected to announce its Q4 2024 earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Trading Down 3.3 %

Shares of NASDAQ ATOS traded down $0.02 during trading hours on Tuesday, reaching $0.72. The stock had a trading volume of 421,413 shares, compared to its average volume of 1,008,812. Atossa Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.31. The firm has a market cap of $91.05 million, a price-to-earnings ratio of -3.29 and a beta of 1.20. The business's fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.12.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE increased its holdings in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 111,475 shares of the company's stock after acquiring an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ATOS shares. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 12th. Ascendiant Capital Markets increased their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research note on Monday, December 9th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.